There seems to be a void in the dots (unless the information is buried in the 10-Q).......

This was the appearance of the product when Baroni was retained.....

PDSG provides products and solutions that enhance the efficiency and effectiveness of mission-critical applications. PDSG's flagship product, the Crossflo DataExchange(R) solution, helps link systems together and facilitates secure data sharing for information exchange initiatives primarily in the healthcare, public safety, and justice markets. Crossflo DataExchange(R) has been designed to work with a number of national data sharing standards and protocols, including Health Level 7, the National Information Exchange Model, and the Global Justice XML Data Model. PDSG's technological innovation is backed by subject matter expertise and proven methodologies and facilitates the rapid exchange of data in mission-critical applications, such as clinical quality improvement and emergency services response management.

http://patriotscientific.com/index.php?option=com_content&task=view&id=229&Itemid=29

Shortly thereafter, the guidance was retracted......

The Company's revenue shortfall is based on its current assessment of the timing for prospective customer projects and other opportunities with various Federal, state and local agencies. These project delays, the general budget environment and lack of historic revenue history for the PDSG products, have created uncertainty to the extent that the Company's management does not feel that it has adequate information on which to reasonably base an updated revenue projection at this time.

http://patriotscientific.com/index.php?option=com_content&task=view&id=230&Itemid=29

And then the reorganization.......

Additionally, the Board expects to receive a favorable independent technical assessment of PDSG's flagship Crossflo DataExchange® product (CDX) within the next two weeks.

http://patriotscientific.com/index.php?option=com_content&task=view&id=241&Itemid=29

Maybe I'm missing something as we have a product that appeared to be fully implemented with guidance retracted due to outside circumstances and now the assessments and studies giving the appearance of a product still in development.........